

Financial Tear Sheet

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.

Stock Performance

FWP (Common Stock)

Exchange NASDAQ GS (US Dollar)

Financial Status Indicator C

Price **\$22.49**

Change (%) ▼ 0.1 (0.44%)

Volume 3,827

52 Week Low \$14.89

Market Cap \$1,064,980,453

Rolling EPS -0.71

PE Ratio 0

Shares Outstanding 47,143,889



Data as of 07/25/17 4:00 p.m. ET

Recent Headlines

07/18/17

Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders

06/14/17

Forward Pharma CEO to Present at the JMP Securities 2017 Life Sciences Conference on June 20, 2017

06/02/17

Forward Pharma CEO to Present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
07/18/17	6-K
06/30/17	6-K
06/20/17	6-K
06/06/17	6-K

Corporate Governance

Claus Bo Svendsen, MD, PhD	CEO
Peder Møller Andersen, MD	COO

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources